Cambridge Investment Research Advisors
SPRY icon

Cambridge Investment Research Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Cambridge Investment Research Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$698K Hold
87,161
– – ﹤0.01% 2641
2026
Q1 		$700K Hold
87,161
– – ﹤0.01% 2501
2025
Q4 		$1.01M Hold
87,161
– – ﹤0.01% 2083
2025
Q3 		$876K Sell
87,161
-1
-0% -$14 ﹤0.01% 2151
2025
Q2 		$1.52M Buy
87,162
+4
+0% +$58 ﹤0.01% 1642
2025
Q1 		$1.1M Hold
87,158
– – ﹤0.01% 1787
2024
Q4 		$920K Hold
87,158
– – ﹤0.01% 1937
2024
Q3 		$1.26M Buy
+87,158
New +$1.04M ﹤0.01% 1690

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Cambridge Investment Research Advisors's SPRY Position: Q2 2026 in Review

Cambridge Investment Research Advisors held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 87,161 shares worth $698K. The position accounts for ﹤0.01% of the portfolio, ranked #2641.

Cambridge Investment Research Advisors first reported a position in SPRY in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.52M in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Cambridge Investment Research Advisors held 87,161 shares of ARS Pharmaceuticals worth $698K as of Q2 2026.
  • Cambridge Investment Research Advisors left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #2641 holding.
  • Cambridge Investment Research Advisors first reported a position in ARS Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Cambridge Investment Research Advisors's ARS Pharmaceuticals position peaked at $1.52M in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.